Skip to content
Screener

Baxter International BAX Care & Connectivity Solutions — Net Sales

Other product segments

Infusion Therapies & Technologies
$981M-1.3%
Drug Compounding
$320M+30.1%
Advanced Surgery
$304M+13.4%
Injectables & Anesthesia
$301M-10.1%
Front Line Care
$270M-2.5%

Similar metrics at other companies

Energizer Holdings logo
ENRAuto Care — Net Sales
$170.1M-2.7%
Scotts Miracle-Gro logo
SMGLawn care — Net Sales
$265.2M-1.6%
Nature's Sunshine Products logo
NATRPersonal care — Net Sales
$6.76M+27.4%
Honeywell International logo
HONSolutions — Net Sales
$486M+11.5%
Perrigo Company logo
PRGOSelf Care — Net Sales
$576.6M-3.7%
Kenvue logo
KVUESelf Care — Net Sales
$1.59B+2.2%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$14.13B+22.3%
Enterprise value$12.33B+22.1%
P/S1.3×+0.2×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028962
(in millions)Three Months Ended March 31, 2026 / U.S.Three Months Ended March 31, 2026 / InternationalThree Months Ended March 31, 2026 / TotalThree Months Ended March 31, 2025 / U.S.Three Months Ended March 31, 2025 / InternationalThree Months Ended March 31, 2025 / Total
Infusion Therapies & Technologies$526$455$981$584$410$994
Advanced Surgery165139304145123268
Medical Products & Therapies6915941,2857295331,262
Care & Connectivity Solutions315120435316111427
Front Line Care1987227020275277
Healthcare Systems & Technologies513192705518186704
Injectables & Anesthesia180121301195140335
Drug Compounding320320246246

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's care & connectivity solutions — net sales?
Baxter International (BAX) reported care & connectivity solutions — net sales of $435M in Q1 2026.
How has Baxter International's care & connectivity solutions — net sales changed year-over-year?
Baxter International's care & connectivity solutions — net sales increased by 1.9% year-over-year, from $427M to $435M.
What is the long-term trend for Baxter International's care & connectivity solutions — net sales?
Over 3 years (2021 to 2025), Baxter International's care & connectivity solutions — net sales has grown at a 137.9% compound annual growth rate (CAGR), from $142M to $1.91B.
What does care & connectivity solutions — net sales mean?
This metric represents the total revenue generated by the Care and Connectivity Solutions business segment, which focuses on hospital-based medical equipment and digital health solutions. It encompasses sales from connected medical devices, smart hospital beds, and patient communication platforms designed to improve clinical workflows. This revenue stream reflects the company's market penetration in the acute care technology space and its ability to integrate digital connectivity into traditional medical hardware.

Ask your AI about Baxter International's care & connectivity solutions — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude